Cargando…
Apoptosis and Molecular Targeting Therapy in Cancer
Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075070/ https://www.ncbi.nlm.nih.gov/pubmed/25013758 http://dx.doi.org/10.1155/2014/150845 |
_version_ | 1782323287185948672 |
---|---|
author | Hassan, Mohamed Watari, Hidemichi AbuAlmaaty, Ali Ohba, Yusuke Sakuragi, Noriaki |
author_facet | Hassan, Mohamed Watari, Hidemichi AbuAlmaaty, Ali Ohba, Yusuke Sakuragi, Noriaki |
author_sort | Hassan, Mohamed |
collection | PubMed |
description | Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while defective apoptosis may promote carcinogenesis. The apoptotic signals are complicated and they are regulated at several levels. The signals of carcinogenesis modulate the central control points of the apoptotic pathways, including inhibitor of apoptosis (IAP) proteins and FLICE-inhibitory protein (c-FLIP). The tumor cells may use some of several molecular mechanisms to suppress apoptosis and acquire resistance to apoptotic agents, for example, by the expression of antiapoptotic proteins such as Bcl-2 or by the downregulation or mutation of proapoptotic proteins such as BAX. In this review, we provide the main regulatory molecules that govern the main basic mechanisms, extrinsic and intrinsic, of apoptosis in normal cells. We discuss how carcinogenesis could be developed via defective apoptotic pathways or their convergence. We listed some molecules which could be targeted to stimulate apoptosis in different cancers. Together, we briefly discuss the development of some promising cancer treatment strategies which target apoptotic inhibitors including Bcl-2 family proteins, IAPs, and c-FLIP for apoptosis induction. |
format | Online Article Text |
id | pubmed-4075070 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40750702014-07-10 Apoptosis and Molecular Targeting Therapy in Cancer Hassan, Mohamed Watari, Hidemichi AbuAlmaaty, Ali Ohba, Yusuke Sakuragi, Noriaki Biomed Res Int Review Article Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while defective apoptosis may promote carcinogenesis. The apoptotic signals are complicated and they are regulated at several levels. The signals of carcinogenesis modulate the central control points of the apoptotic pathways, including inhibitor of apoptosis (IAP) proteins and FLICE-inhibitory protein (c-FLIP). The tumor cells may use some of several molecular mechanisms to suppress apoptosis and acquire resistance to apoptotic agents, for example, by the expression of antiapoptotic proteins such as Bcl-2 or by the downregulation or mutation of proapoptotic proteins such as BAX. In this review, we provide the main regulatory molecules that govern the main basic mechanisms, extrinsic and intrinsic, of apoptosis in normal cells. We discuss how carcinogenesis could be developed via defective apoptotic pathways or their convergence. We listed some molecules which could be targeted to stimulate apoptosis in different cancers. Together, we briefly discuss the development of some promising cancer treatment strategies which target apoptotic inhibitors including Bcl-2 family proteins, IAPs, and c-FLIP for apoptosis induction. Hindawi Publishing Corporation 2014 2014-06-12 /pmc/articles/PMC4075070/ /pubmed/25013758 http://dx.doi.org/10.1155/2014/150845 Text en Copyright © 2014 Mohamed Hassan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Hassan, Mohamed Watari, Hidemichi AbuAlmaaty, Ali Ohba, Yusuke Sakuragi, Noriaki Apoptosis and Molecular Targeting Therapy in Cancer |
title | Apoptosis and Molecular Targeting Therapy in Cancer |
title_full | Apoptosis and Molecular Targeting Therapy in Cancer |
title_fullStr | Apoptosis and Molecular Targeting Therapy in Cancer |
title_full_unstemmed | Apoptosis and Molecular Targeting Therapy in Cancer |
title_short | Apoptosis and Molecular Targeting Therapy in Cancer |
title_sort | apoptosis and molecular targeting therapy in cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075070/ https://www.ncbi.nlm.nih.gov/pubmed/25013758 http://dx.doi.org/10.1155/2014/150845 |
work_keys_str_mv | AT hassanmohamed apoptosisandmoleculartargetingtherapyincancer AT watarihidemichi apoptosisandmoleculartargetingtherapyincancer AT abualmaatyali apoptosisandmoleculartargetingtherapyincancer AT ohbayusuke apoptosisandmoleculartargetingtherapyincancer AT sakuraginoriaki apoptosisandmoleculartargetingtherapyincancer |